Loading news...
Shares of DIAGNOS Inc. (OTCMKTS:DGNOF - Get Free Report) shot up 2.6% during trading on Wednesday. The stock traded as high as $0.2145 and last traded at $0.2125. 25,000 shares were traded during mid-day trading, a decline of 72% from the average session volume of 88,814 shares. The stock had previously closed at $0.2072.
BROSSARD, Quebec, March 05, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to amend the terms of an aggregate amount of $510,000 of unsecured convertible debentures (each, a Debenture) issued as part of a non-brokered private placement of units initially announced on March 1, 2022, and subsequently amended on March 1, 2025 (pleaser refer to the press release dated February 28, 2025). The amendments are as follows:
BROSSARD, Quebec, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical eye-related health issues using advanced technology based on Artificial Intelligence (AI), is pleased to announce that it will be presenting at the Centurion One Capital 9th Annual Conference in Toronto, Canada March 5th 2026.
DIAGNOS Inc. (OTCMKTS:DGNOF - Get Free Report)'s share price traded up 1.6% during trading on Tuesday. The company traded as high as $0.2189 and last traded at $0.2175. 300,800 shares were traded during trading, an increase of 261% from the average session volume of 83,233 shares. The stock had previously closed at $0.2140. DIAGNOS
BROSSARD, Quebec, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical eye-related health issues using advanced technology based on Artificial Intelligence (AI), and the École de technologie supérieure (ÉTS) today announced a major federal investment exceeding 1 Million $CAD to accelerate the development of next-generation artificial intelligence for retinal image analysis.
BROSSARD, Quebec, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces the engagement of Investor Brand Network (“IBN”) to provide corporate communication and awareness solutions to the Corporation.
Fathom (NASDAQ: FTHM - Get Free Report) and DIAGNOS (OTCMKTS:DGNOF - Get Free Report) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk. Earnings and Valuation This table compares Fathom and
Not for distribution to United States newswire services or for dissemination in the United States. BROSSARD, Quebec, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSXV: ADK and OTCQB: DGNOF) is pleased to announce the successful closing of its previously announced upsized private placement (the “Offering”) of units of the Company (the “Units”).
Priority Technology (NASDAQ: PRTH - Get Free Report) and DIAGNOS (OTCMKTS:DGNOF - Get Free Report) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Valuation and Earnings This table compares Priority
BROSSARD, Quebec, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 3,502,931 stock warrants (each a “Warrant”) issued as part of a non-brokered private placement of units initially announced on June 5, 2024 and set to expire on December 5, 2025.
Not for distribution to United States newswire services or for dissemination in the United States. BROSSARD, Quebec, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSXV: ADK and OTCQB: DGNOF) is pleased to announce that it has engaged Centurion One Capital Corp. (the “Lead Agent”) as lead agent and sole bookrunner, in connection with a brokered private placement to raise up to approximately $2,000,000 (the “Offering“) through the sale of up to 6,666,667 units (“Units“) at an issue price of $0.30 per Unit (the “Issue Price”) on a best efforts basis.
SAIHEAT (NASDAQ: SAIH - Get Free Report) and DIAGNOS (OTCMKTS:DGNOF - Get Free Report) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Earnings and Valuation This table compares SAIHEAT and
BROSSARD, Quebec, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 1,125,000 stock warrants (each a “Warrant”) issued as part of a non-brokered private placement of units initially announced on May 9, 2024 and set to expire on November 9, 2025.
Brossard, Quebec--(Newsfile Corp. - October 15, 2025) - Diagnos Inc. (TSXV: ADK) (OTCQB: DGNOF) (FSE: 4D4A) ("DIAGNOS" or the "Corporation"), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), is pleased to announce it will be presenting at the Centurion One Capital 3rd Annual Bahamas Summit, a two-day invitation only event taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 28th to Wednesday, October 29th, 2025, in Nassau, Bahamas. André Larente, CEO of DIAGNOS, will be presenting and attending investor meetings as well as participating on a panel discussion during the event.
BROSSARD, Quebec, Sept. 25, 2025 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using Artificial Intelligence (AI) technologies, announces the voting results of the annual meeting of the shareholders held earlier today.
BROSSARD, Quebec, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it has closed a non-brokered private placement (“Private placement”), initially announced on September 3, 2025, of 10 units (each a “Unit”) issued at a price of $10,000 per Unit, for gross proceeds of $100,000.
BROSSARD, Quebec, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 650,000 stock warrants (each a “Warrant”) issued as part of a non-brokered private placement of units initially announced on March 22, 2024. The Warrants initial exercise period is set to expire on September 22, 2025.
BROSSARD, Quebec, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 1,414,286 stock warrants (each a “Warrant”) issued as part of a non-brokered private placement of units initially announced on February 27, 2024. The Warrants initial exercise period is set to expire on August 27, 2025.
BROSSARD, Quebec, June 10, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), is thrilled to announce that Mr. Ed Weiner has joined the Corporation's Advisory Board.
BROSSARD, Quebec, June 04, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), is thrilled to announce that Dr. Tomas J. Philipson has joined the Corporation's Advisory Board.